title: Evaluation of cisplatin plasma levels in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
abstract: Introduction Peritoneal surface malignancies have long been regarded as incurable, however, they can be treated with cytoreductive surgery in addition to hyperthermic intraperitoneal chemotherapy. This approach is associated with an increase in morbidity and mortality, unless hyperhydration is provided in a timely manner. Methods Cisplatin (CDDP) is the most widely used chemotherapeutic agent. Plasma levels of cisplatin (CDDP), a widely used chemotherapeutic agent, were measured before, during, and after the procedure. This was done in order to identify the window of highest risk as a function of drug concentrations, assuming a dose-dependent effect. Results Plasma levels of CDDP peak during perfusion. The concentration remains high until the 4th post-operative day and returns to pre-operative levels by the 7th post-operative day. Conclusions Our findings suggest that ensuring hyperhydration as well as infusing albumin and fresh frozen plasma may be of particular value for at least the first 4 days after the procedure.
authors.affiliation: a Department of Human Pathology , University of Messina , Messina , Italy ;
authors.forename: Francesco
authors.initials: F
authors.lastname: Fleres
authors.affiliation: a Department of Human Pathology , University of Messina , Messina , Italy ;
authors.forename: Edoardo
authors.initials: E
authors.lastname: Saladino
authors.affiliation: b Department of S.A.S.T.A.S. , University of Messina , Messina , Italy ;
authors.forename: Rosaria
authors.initials: R
authors.lastname: Catanoso
authors.affiliation: c Department of Clinical and Experimental Medicine , University of Messina , Messina , Italy ;
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Arcoraci
authors.affiliation: d Anesthesiology and Neuroreanimation Unit, University of Messina , Messina , Italy.
authors.forename: Tommaso
authors.initials: T
authors.lastname: Mandolfino
authors.affiliation: a Department of Human Pathology , University of Messina , Messina , Italy ;
authors.forename: Eugenio
authors.initials: E
authors.lastname: Cucinotta
authors.affiliation: a Department of Human Pathology , University of Messina , Messina , Italy ;
authors.forename: Antonio
authors.initials: A
authors.lastname: Macrì
mesh_terms: D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage / Q000097:blood*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin
keywords: Cisplatin; HIPEC; outcome; serum levels